Stocks in Play

5/17/2018 - 1:37 PM EST - Abattis Bioceuticals Corp. : Announced it has entered into a non-binding letter of intent with Cannamedix Inc. to provide Cannamedix with, among other things, pesticide-free cannabinoid-containing oils, research and development, analytical and regulatory services and access to Abattis’s distribution and marketing channels to support the development and commercialization of new CBD-infused nutraceuticals and natural health products. Cannamedix is a Calgary-based healthcare provider focused on the use of traditional and alternative therapies to address health conditions, from pain management to integrative cancer care. Pursuant to the LOI, Abattis and Cannamedix have agreed to negotiate in good faith the terms of a definitive agreement respecting the terms of their partnership. "Abattis is pleased to support Cannamedix’s efforts to develop and distribute what could be one of the first lines of cannabinoid-infused nutraceuticals and natural health products in Canada," stated Rob Abenante, President and CEO of Abattis. Abattis Bioceuticals Corp. shares ATT:CNX are trading off 2.44 percent at $0.20.